Sharing Clinical Reports Project
Friday, May 03, 2013
As the Supreme Court decides whether genes can be patented, one geneticist has taken matters into his own hands. Dr. Robert Nussbaum is less worried about the owning of genes and more concerned about the monopoly that private companies have over genetic intellectual property – specifically what the mutations in a gene might mean for his patient's health. He tells Brooke how he’s challenging the stranglehold on that information one patient at a time.
We contacted Myriad for comment and they responded:
“Nothing is more important to Myriad than helping to save and improve peoples’ lives and more than one million patients have benefitted from Myriad’s BRACAnalysis test for hereditary breast and ovarian cancer. As a result of Myriad’s $500 million investment in R&D, today more than 95 percent of patients in the U.S. have access to the BRACAnalysis test through private insurance or other coverage, and patients’ average out-of-pocket cost is only $100. Myriad also offers financial assistance programs or free testing for uninsured patients or those in need."
Modest Mouse - Here It Comes
- The Cancer Show
- Podcast Extra: After Oregon
- That Facebook Disclaimer? Ignore It.
- The Cancer Show: Part I
- The Cancer Show: Part 2
- Pope-ular Opinion
- The Breaking News Consumer's Handbook
- Looking Backward On The Presidency Of Donald Trump
- Every Edit You've Ever Made to a Facebook Post Is Visible
- Speaking in Tongues